Ananda Pharma plc (AQSE: ANA) (OTC: ANANF), a UK-based biopharmaceutical company focused on cannabidiol-based medicines, on Monday announced the completion of dosing in its Phase 1 pharmacokinetic (PK) study for MRX1 CBD. This achievement marks the Last Participant, Last Dose (LPLD) milestone in the trial conducted in Melbourne, Australia.

All 19 healthy adult volunteers (9 male, 10 female) across two dosing cohorts have received their final MRX1 dose.

Next steps will include database locking and commencement of data analysis. Safety and tolerability readouts are expected in Q4 2025, with a draft clinical trial report targeted for Q1 2026.

Data from this trial will be utilised for FDA filings and to inform the design of future trials.

This milestone represents a significant step in Ananda's mission to develop regulatory-approved cannabidiol medicines to address complex conditions such as endometriosis and chemotherapy-induced peripheral neuropathy.

Ananda Pharma is advancing cannabinoid therapeutics with clinical programmes supported by NHS Scotland and NIHR, led by a team of world-class scientists including experts from the University of Edinburgh.